En direct

Le Centre de Recherche en Cancérologie de Marseille fête ses 50 ans ! -

Aug 2009 The Prostate

Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.


Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J


Botulinum toxin type A (BTA) intraprostatic injection induces an improvement of urinary symptoms related to benign prostatic hypertrophy (BPH). Infra-clinical prostate cancer (PCa) foci and pre-neoplasic lesions occur concomitantly with BPH in a significant number of patients. The objective of this study was to address whether BTA influences the growth of prostate tumors.

Lire l‘article